Hyperthermia European Adjuvant Trial (HEAT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by Klinikum der Universitaet Muenchen, Grosshadern
Sponsor:
Collaborators:
The European Society for Hyperthermic Oncology
Ludwig-Maximilians - University of Munich
Information provided by (Responsible Party):
Rolf D. Issels, Klinikum der Universitaet Muenchen, Grosshadern
ClinicalTrials.gov Identifier:
NCT01077427
First received: February 25, 2010
Last updated: July 18, 2012
Last verified: July 2012

February 25, 2010
July 18, 2012
March 2012
March 2015   (final data collection date for primary outcome measure)
Disease-free survival (DFS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months ] [ Designated as safety issue: No ]
Disease-free survival (DFS) [ Time Frame: Interim analyses after 26 and 39 months after start of the study; final analysis after 60 months after start of the study; follow-up every 3 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01077427 on ClinicalTrials.gov Archive Site
Overall survival (OS) [ Time Frame: From date of randomization until the date of death from any cause assessed up to 60 months ] [ Designated as safety issue: No ]
Overall survival (OS) [ Time Frame: Interim analyses after 26 and 39 months after start of the study; final analysis after 60 months after start of the study; follow-up every 3 months ] [ Designated as safety issue: No ]
  • Toxicity [ Time Frame: Permanent assessment ] [ Designated as safety issue: Yes ]
  • Quality of Life [ Time Frame: Permanent assessment ] [ Designated as safety issue: No ]
    EORTC QLQ C30
Not Provided
 
Hyperthermia European Adjuvant Trial
A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Alone (Arm G) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH)

Improvement of the clinical outcome in patients with resectable pancreatic carcinoma through an intensified adjuvant treatment with additional application of cisplatin and regional deep hyperthermia.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Resected Pancreatic Adenocarcinoma
  • Device: Gemcitabine + Cisplatin + regional hyperthermia

    Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²) Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²) Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course

    * as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17

  • Drug: Gemcitabine
    Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)
  • Active Comparator: Gemcitabine
    Intervention: Drug: Gemcitabine
  • Experimental: Gemcitabine + Cisplatin + regional hyperthermia
    Intervention: Device: Gemcitabine + Cisplatin + regional hyperthermia
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
336
March 2017
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Any ductal adenocarcinoma of the pancreas confirmed by histology
  2. Previous R0 or R1 resection of pancreatic tumor with a standardized procedure
  3. No other previous or concomitant treatment of pancreatic carcinoma like radiation, neoadjuvant therapy or immunotherapy
  4. No tumor recurrence after surgery
  5. Postoperative tumor marker (CEA/CA19-9) ≤ 2.5 x upper limit of normal (ULN) to be documented within 1 week prior to randomization
  6. Performance status ECOG 0-2
  7. Adequate bone marrow function defined as

    • WBC count ≥ 3.5 x 109/L and
    • platelets ≥ 150 x 109/L and
    • haemoglobin ≥ 9 g/dl documented within 1 week prior to randomization
  8. Adequate renal function defined as

    • serum creatinine ≤ 1.2 mg/dL and
    • calculated GFR ≥ 60 mL/min documented within 1 week prior to randomization
  9. Adequate coagulatory function defined as

    • Quick-value ≥ 70% and
    • aPTT ≤ 1.5 x ULN documented within 1 week prior to randomization
  10. Transaminases (AST, ALT) ≤ 3 x ULN and bilirubin ≤ 2 x ULN documented within 1 week prior to randomization
  11. At least 18 years of age
  12. Women with childbearing potential and fertile men must use adequate contraceptive measures during and for at least 3 months (female) and 6 months (male) after completion of study therapy (Adequate methods for women are oral contraceptives with estrogen and progesterone, vaginal rings, contraceptive patches, estrogen-free ovulation inhibitors, intrauterine devices with progesterone,3-month injections with depot progesterone, implants setting free progesterone, abstinence or sterilization (vasectomy) of the male partner. Men must use condoms.)
  13. Women with childbearing potential must have a negative pregnancy test within 1 week prior to randomization (postmenopausal women with amenorrhea for more than 1 year are regarded as having no childbearing potential)
  14. Written informed consent

Exclusion criteria:

  1. Cystic carcinoma of the pancreas
  2. Periampullary, papillary cancer
  3. Metastatic disease
  4. Presence of an active infection grade 3 or higher
  5. Other severe disease which could impair the patient's ability to participate in the study according to the investigator's opinion
  6. Pregnant or breastfeeding women
  7. Known allergies or contraindications with regard to substances or procedures of study therapy
  8. Severe, non-healing wounds, ulcers or bone fractures
  9. Participation in another clinical trial during this study or within 4 weeks prior to randomization
  10. Past or current abuse of illegal or legal drugs or alcohol
  11. Other primary malignant diseases in the medical history during the last 5 years (exceptions: carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin).
  12. Permanent cardiac pacemaker
  13. Gross adiposity defined as BMI > 40 kg/m²
  14. Treatment with regional hyperthermia not possible for technical reasons (e.g. metal implant)
Both
18 Years to 75 Years
No
Contact: Rolf D. Issels, MD, PhD +49-89-7095-7776 heat@med.uni-muenchen.de
Germany
 
NCT01077427
115-09, 2008-004802-14, AIO-PAK-0111
Yes
Rolf D. Issels, Klinikum der Universitaet Muenchen, Grosshadern
Klinikum der Universitaet Muenchen, Grosshadern
  • The European Society for Hyperthermic Oncology
  • Ludwig-Maximilians - University of Munich
Principal Investigator: Rolf D. Issels, MD, PhD Klinikum Grosshadern, Medical Center, University of Munich, Germany
Klinikum der Universitaet Muenchen, Grosshadern
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP